FI95375B - Analogiförfarande för framställning av den terapeutiskt aktiva d-isomeren av medetomidin - Google Patents

Analogiförfarande för framställning av den terapeutiskt aktiva d-isomeren av medetomidin

Info

Publication number
FI95375B
FI95375B FI882819A FI882819A FI95375B FI 95375 B FI95375 B FI 95375B FI 882819 A FI882819 A FI 882819A FI 882819 A FI882819 A FI 882819A FI 95375 B FI95375 B FI 95375B
Authority
FI
Finland
Prior art keywords
medetomidine
isomer
preparation
therapeutically active
analogous process
Prior art date
Application number
FI882819A
Other languages
English (en)
Finnish (fi)
Other versions
FI882819A0 (sv
FI95375C (sv
FI882819A (sv
Inventor
Arto Johannes Karjalainen
Raimo Einari Virtanen
Eino Juhani Savolainen
Original Assignee
Farmos Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10620775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI95375(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Farmos Oy filed Critical Farmos Oy
Publication of FI882819A0 publication Critical patent/FI882819A0/sv
Publication of FI882819A publication Critical patent/FI882819A/sv
Application granted granted Critical
Publication of FI95375B publication Critical patent/FI95375B/sv
Publication of FI95375C publication Critical patent/FI95375C/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Optical Record Carriers And Manufacture Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI882819A 1987-07-16 1988-06-14 Analogiförfarande för framställning av den terapeutiskt aktiva d-isomeren av medetomidin FI95375C (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8716803A GB2206880B (en) 1987-07-16 1987-07-16 Optical isomers of an imidazole derivative
GB8716803 1987-07-16

Publications (4)

Publication Number Publication Date
FI882819A0 FI882819A0 (sv) 1988-06-14
FI882819A FI882819A (sv) 1989-01-17
FI95375B true FI95375B (sv) 1995-10-13
FI95375C FI95375C (sv) 1996-01-25

Family

ID=10620775

Family Applications (1)

Application Number Title Priority Date Filing Date
FI882819A FI95375C (sv) 1987-07-16 1988-06-14 Analogiförfarande för framställning av den terapeutiskt aktiva d-isomeren av medetomidin

Country Status (29)

Country Link
US (1) US4910214A (sv)
EP (1) EP0300652B1 (sv)
JP (1) JPH0625138B2 (sv)
KR (1) KR940007311B1 (sv)
CN (1) CN1022323C (sv)
AT (1) ATE71941T1 (sv)
AU (1) AU600839B2 (sv)
BG (1) BG60473B2 (sv)
CA (1) CA1337659C (sv)
CY (2) CY1787A (sv)
DD (1) DD281807A5 (sv)
DE (2) DE10399005I2 (sv)
DK (1) DK165788C (sv)
ES (1) ES2038757T3 (sv)
FI (1) FI95375C (sv)
GB (1) GB2206880B (sv)
GR (1) GR3003878T3 (sv)
HK (1) HK56094A (sv)
HU (1) HU198693B (sv)
IE (1) IE60456B1 (sv)
IL (1) IL87076A0 (sv)
LU (1) LU91010I2 (sv)
NL (1) NL300117I2 (sv)
NO (2) NO170579C (sv)
NZ (1) NZ225362A (sv)
PT (1) PT88013B (sv)
SU (1) SU1648248A3 (sv)
UA (1) UA5560A1 (sv)
ZA (1) ZA885134B (sv)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2215206B (en) * 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB2281206A (en) * 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
IN187238B (sv) * 1995-06-30 2002-03-09 Astra Ab
GB9521680D0 (en) * 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
US5866579A (en) 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
CA2388979C (en) 1999-10-29 2010-09-14 Orion Corporation Treatment or prevention of hypotension and shock with use of an imidazole derivative
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
DK2018160T3 (da) 2006-03-16 2012-02-06 Tris Pharma Inc Modificeret depotformuleringer indeholdende lægemiddel-ionbytterharpikskomplekser
US7795263B2 (en) * 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
WO2010065547A1 (en) * 2008-12-01 2010-06-10 Map Pharmaceuticals, Inc. Inhalation delivery methods and devices
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
AU2010248776B2 (en) * 2009-05-15 2013-06-06 Baudax Bio, Inc. Sublingual dexmedetomidine compositions and methods of use thereof
CN101671305A (zh) * 2009-09-29 2010-03-17 北京华禧联合科技发展有限公司 一种拆分美托咪定的左旋及右旋对映体的方法
CN102464619A (zh) * 2010-11-17 2012-05-23 桑迪亚医药技术(上海)有限责任公司 一种左旋4-[1-(2,3-二甲基苯基)乙基]-1r-咪唑消旋化方法
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
WO2013069025A1 (en) 2011-11-11 2013-05-16 Neon Laboratories Ltd. "process for the preparation of dexmedetomidine"
SG11201403094TA (en) 2011-12-11 2014-10-30 Recro Pharma Inc Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
ITMI20120311A1 (it) * 2012-02-29 2013-08-30 Edmond Pharma Srl Procedimento per la risoluzione di medetomidina e recupero dell'enantiomero indesiderato
DK2884961T3 (en) 2012-08-15 2019-04-23 Tris Pharma Inc METHYLPHENIDATE TABLE WITH EXTENDED RELEASE
CA2884926C (en) 2012-10-15 2021-09-21 Orion Corporation A veterinary method of alleviating noise aversion
TWI704933B (zh) 2013-10-07 2020-09-21 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
KR101831290B1 (ko) 2013-10-07 2018-02-22 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
CN105764496B (zh) 2013-10-07 2020-09-25 帝国制药美国公司 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物
CN105175339B (zh) * 2015-10-09 2018-01-16 辰欣药业股份有限公司 一种制备盐酸右美托咪定的方法
US9717796B1 (en) 2016-04-20 2017-08-01 Slypharma, Llc Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
FR3054218B1 (fr) * 2016-07-22 2020-03-06 Universite De Rouen Procede de dedoublement de sels de baclofene
US11160791B2 (en) 2018-11-01 2021-11-02 Medefil, Inc. Dexmedetomidine injection premix formulation in ready to use (RTU) bags
CN114671811A (zh) * 2022-04-14 2022-06-28 南京正科医药股份有限公司 一种右美托咪定拆分副产物的外消旋化回收方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
GB2092569B (en) * 1981-02-05 1984-09-19 Farmos Oy Substituted imidazole derivatives and their preparation and use
GB2101114B (en) * 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
DE3531682A1 (de) * 1985-09-05 1987-03-12 Thomae Gmbh Dr K (+)-6-chlor-5,10-dihydro-5-((1-methyl-4- piperidinyl)acetyl)-11h-dibenzo(b,e)(1,4) diazepin-11-on, seine isolierung und verwendung als arzneimittel

Also Published As

Publication number Publication date
ZA885134B (en) 1989-04-26
HK56094A (en) 1994-06-03
GR3003878T3 (sv) 1993-03-16
CA1337659C (en) 1995-11-28
BG60473B2 (bg) 1995-04-28
FI882819A0 (sv) 1988-06-14
HUT48218A (en) 1989-05-29
GB2206880A (en) 1989-01-18
ES2038757T3 (es) 1993-08-01
FI95375C (sv) 1996-01-25
DE10399005I1 (de) 2003-06-05
EP0300652B1 (en) 1992-01-22
PT88013B (pt) 1995-03-01
DK386288A (da) 1989-01-17
NO883155D0 (no) 1988-07-15
IE60456B1 (en) 1994-07-13
SU1648248A3 (ru) 1991-05-07
DE3867945D1 (de) 1992-03-05
NO883155L (no) 1989-01-17
DK165788C (da) 1993-06-14
CN1022323C (zh) 1993-10-06
JPS6434968A (en) 1989-02-06
NO170579C (no) 1992-11-04
PT88013A (pt) 1989-06-30
CN1030576A (zh) 1989-01-25
UA5560A1 (uk) 1994-12-28
ATE71941T1 (de) 1992-02-15
DD281807A5 (de) 1990-08-22
EP0300652A1 (en) 1989-01-25
LU91010I2 (fr) 2003-06-19
CY2004006I1 (el) 2009-11-04
FI882819A (sv) 1989-01-17
DE10399005I2 (de) 2012-06-06
DK386288D0 (da) 1988-07-11
GB2206880B (en) 1991-04-24
CY1787A (en) 1995-10-20
AU600839B2 (en) 1990-08-23
NL300117I1 (nl) 2003-05-01
GB8716803D0 (en) 1987-08-19
NZ225362A (en) 1990-07-26
CY2004006I2 (el) 2009-11-04
IL87076A0 (en) 1988-12-30
JPH0625138B2 (ja) 1994-04-06
HU198693B (en) 1989-11-28
KR890002030A (ko) 1989-04-07
US4910214A (en) 1990-03-20
NO2003004I2 (no) 2005-03-21
DK165788B (da) 1993-01-18
KR940007311B1 (ko) 1994-08-12
IE882174L (en) 1989-01-16
AU1894188A (en) 1989-01-19
NO170579B (no) 1992-07-27
NL300117I2 (nl) 2003-10-01

Similar Documents

Publication Publication Date Title
FI95375B (sv) Analogiförfarande för framställning av den terapeutiskt aktiva d-isomeren av medetomidin
FI873205A0 (sv) Förfarande för framställning av terapeutiskt aktiva bensimidazolderivat
LU81297A1 (fr) Procede enzymatique microbiologique pour la production d'aminoacides optiquement actifs en partant d'hydantoines et/ou de derives carbamoyle racemiques
FI89046C (sv) Förfarande för framställning av terapeutiskt aktiv bensimidazolförenin g
FI880467A (sv) Förfarande för framställning av terapeutiskt användbara substituerade 3,4-dihydro-2H-benzopyraner
FI871087A (sv) Förfarande för framställning av terapeutiskt användbara 1,2,3,4-tetrahydro-3-karbamoyl-2-tioxo/oxo-5-pyrimidinkarboxylsyraderivat
FI884660A (sv) Förfarande för framställning av terapeutiskt aktiva 2,2-dimetylkromenderivat
FI99013B (sv) Analogiförfarande för framställning av terapeutiskt användbara bensimidazolderivat
FI893471A (sv) Förfarande för framställning av (alkylditio)kinolinderivat med antiulcer aktivitet
FI893121A0 (sv) Förfarande för framställning av terapeutiskt aktiva 6,21-dimetyl-19-norprogestronderivat
ES8700226A1 (es) Un procedimiento para la preparacion en forma cristalina de una mezcla de sales diastereomericas del ester 1-pivaloiloxietilico de (s)-3-(3,4-dihidroxifenil)-2-metilalanina
BG44022A3 (en) Method for preparing of ester derivatives of diphenylether oximes
HUT39730A (en) Process for production of derivatives of biologically active benzimidazole, benzoxazole and benztiazole
NO175099C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 1,3,5-tritianderivater
IT8519972A0 (it) Testata autocentrante per il supporto rotante di alberi esimili.

Legal Events

Date Code Title Description
FG Patent granted

Owner name: ORION-YHTYMAE OY

BB Publication of examined application
GB Transfer or assigment of application

Owner name: ORION-YHTYMAE OY

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20030004

FG Patent granted

Owner name: ORION-YHTYMAE OY

SPCG Supplementary protection certificate granted

Spc suppl protection certif: L196

Extension date: 20130613